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Editorial on theResearch Topic
Emerging Biomarkers in Genitourinary Tumors
This is a contemporary update in the field of Emerging Biomarkers in Genitourinary Tumors.
This series of papers, published in Frontiers in Oncology, section Genitourinary Oncology, by
internationally renowned researchers, covers five major topics: (1). Identification of immunological
biomarkers in genitourinary cancers; (2). New prostate cancer targets for imaging and therapy; (3)
Liquid molecular biomarkers in genitourinary tumors; (4) Emerging biomarkers in testicular germ
cell tumors; and (5) Future perspectives on molecular biomarkers in genitourinary tumors: toward
a personalized approach to diagnosis, prognosis and prediction of response to therapy.
The first two papers are related to the Identification of immunological biomarkers in
genitourinary cancers. In particular, the first, by Cimadamore et al., deals with the biological
relationship between the gut microbiome and the immune system, in particular cancer
development and treatment. As an example, Akkermansia muciniphila is a commensal associated
with excellent clinical outcomes in renal cell carcinoma and non-small cell lung cancer. Interesting
results have emerged on the microbiome in prostate cancer (PCa) patients, with specific bacteria as
potential biomarkers in risk stratification. Abnormal gut microbiome composition could also have
an influence on primary resistance to PD-1 blockade in mice xenografts and patients with cancer.
The contribution by Lopez-Beltran et al. deals with the identification of novel immunological
biomarkers in kidney cancers. Robust and reliable biomarkers are crucial for patient’s selection for
treatment with immunomodulatory drugs. PD-L1 expression is predictive of better response from
both PD-1 and PD-L1 inhibitors in a variety of tumor types including RCC. A single biomarker for
patient selection may not be feasible, given that immune responses are dynamic and evolve over
time. A multidisciplinary approach is very much needed to fully develop the current and future
value of immune checkpoint inhibitors in clinical practice.
The third paper of the whole series, by Cimadamore et al., deals with New PCa targets
for imaging and therapy, focusing on Prostate-Specific Membrane Antigen (PSMA). This
contribution reviews the current role of PSMA as a marker for PCa diagnosis, imaging and
therapy. PSMA is expressed in the epithelial cells of the prostate and is strongly upregulated
in PCa, with elevated expression correlating with androgen independence, metastasis and
progression. PSMA has been found to be an active target of investigation by several approaches,
including the successful use of small molecule inhibitors, RNA aptamer conjugates, PSMA-
based immunotherapy, and PSMA-targeted prodrug therapy. The next three papers deals
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with Liquid molecular biomarkers in genitourinary tumors. The
first of the three, by Di Nunno et al., is related to recent
advances in liquid biopsy in patients with castration resistant
PCa. The selection of patients more likely to benefit from a
specific therapeutic approach still remains a key issue as well
as the early identification of patients with aggressive disease
which could benefit from a more aggressive treatment strategy.
They review the literature to explore current knowledge on
liquid biopsy in PCa focusing on possible future applications.
In particular they focus on circulating DNA and circulating
tumor cells as a promising and attractive approach despite to
date practical applications of these techniques are few and not
validated. The paper by Santoni et al. is an updates on urine
markers in superficial and non-superficial bladder cancer (BCa).
There is a growing evidence toward the use of minimally invasive
“liquid biopsy” to identify new biomarkers. DNA- and RNA-
based markers in body fluids such as blood and urine are
promising potential markers in diagnostic, prognostic, predictive
and monitoring BCa. However, proteomic and genomic data
must to be validated in well-designed multicenter clinical studies,
before to be employed in clinic oncology. The paper by Santoni
et al. deals with recent findings and future challenges of
circulating tumor cells (CTCs) in renal cell carcinoma (Santoni
et al.). Renal Cell Carcinoma (RCC) may absolutely benefit
from the development of non-invasive and reliable biomarkers,
allowing early and timely personalized treatment changes. The
introduction of CTC analysis within daily clinical practice for
patients with RCC seems still so far at the moment. However, the
advances obtained in the last 5 years in isolating and analyzing
CTCs bring optimism about the future therapeutic landscape in
RCC patients.
The contribution by Chovanec et al. deals with Emerging
biomarkers in testicular germ cell tumors (GCTs). The ability
to predict prognosis and treatment response in GCTs did not
improve for many years. Clinical trials with novel targeting
agents that were conducted in refractory GCT patients have
proven to have negative outcomes. Novel biomarkers have
emerged in the field of GCT oncology. Since then, oncology
has exploded with various molecular biomarkers to further
refine the prognosis and treatment of malignancies. This review
summarizes the current knowledge in the research of novel
biomarkers in GCTs.
The remaining two papers deal with Future perspectives
on molecular biomarkers in genitourinary tumors: toward a
personalized approach to diagnosis, prognosis and prediction
of response to therapy. The paper by Giulietti et al. is related
to emerging biomarkers in BCa identified by network analysis
of transcriptomic data. Such complex gene interaction networks
can be revealed by a recently developed systems approach called
Weighted Gene Co-expression Network Analysis (WGCNA).
In this review, the authors focused on the studies where
the WGCNA approach has been applied to analyze gene
expression data deriving from BCa samples. The paper by
Giunchi et al. is a perspective article on emerging molecular
technologies in genitourinary tumors. In particular, they deal
with wide spectrum mutational analyses using next generation
sequencing (NGS) platforms that will soon represent the
standard-of-care technologies for the assessment of genetic
variants in genitourinary tumors. They also deal with genome-
wide trascriptome analyses which include gene expression
profiling, miRNA and non-coding RNA profiling and RNA
sequencing. Toward the end of the contribution they refer to
patient-derived xenografts (PDX), i.e., mouse models where
disaggregated cells or little fragments of human tumors are
implanted into immunodeficient mice. The establishment of a
PDX allows treating and monitoring the response to treatment
of the original tumor in vivo in the mouse, instead of the patient,
providing the best therapeutic selection at the same time.
CONCLUSIONS
The identification of effective biomarkers has becoming a
major focus in cancer research, mainly due to the necessity of
selecting potentially responsive patients in order to improve their
outcomes, as well as to reduce the toxicity and costs related to
ineffective treatments. This Research Topic aims to include the
description of these emerging techniques and identify the most
promising biomarkers in genitourinary tumors.
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